Constitutive beta cell expression of IL-12 does not perturb self-tolerance but intensifies established autoimmune diabetes.

A Holz, K Brett, M B Oldstone
Author Information
  1. A Holz: Viral-Immunobiology Laboratory, Division of Virology, Department of Neuropharmacology, The Scripps Research Institute, La Jolla, California 92037, USA.

Abstract

To analyze the function of the Th1-promoting cytokine IL-12 in vivo, we generated transgenic (tg) mice (RIP-IL12 mice) whose pancreatic beta cells constitutively express bioactive IL-12 or one of its components, p35 or p40. In contrast to non-tg littermates or single-tg RIP-p35 and RIP-p40 mice, RIP-IL12 mice developed a marked pancreatic infiltration of lymphocytes and macrophages, mainly around islets. Expression of bioactive IL-12 primarily upregulated transcript levels of IFN-inducible protein-10 (IP-10), RANTES, IFN-gamma, and TNF-alpha in the pancreas. Despite the substantial recruitment of mononuclear cells, no biochemical or clinical disease was evident in the exocrine or endocrine pancreas. Coexpression of lymphocytic choriomeningitis virus (LCMV) proteins with IL-12 in the beta cells failed to spontaneously activate or expand antigen-specific anti-self/viral T cells in uninfected tg animals. However, when RIP-IL12 x RIP-LCMV tg mice were infected with LCMV, antigen-specific anti-self/viral T cells were induced, which led to an acceleration in the kinetics and severity of insulin-dependent diabetes mellitus (IDDM). Thus, the ectopic expression of IL-12 does not spontaneously break tolerance and activate antigen-specific T cells in the periphery, but it does worsen ongoing autoimmune disease.

References

  1. J Immunol. 2000 May 1;164(9):4481-92 [PMID: 10779748]
  2. Cell Mol Life Sci. 1999 Sep;55(12):1610-25 [PMID: 10526578]
  3. J Immunol. 2000 Nov 15;165(10):5945-53 [PMID: 11067957]
  4. Diabetes. 2000 Nov;49(11):1801-9 [PMID: 11078446]
  5. Nat Med. 2001 Feb;7(2):206-14 [PMID: 11175852]
  6. Annu Rev Immunol. 2001;19:131-61 [PMID: 11244033]
  7. Nat Med. 2001 Aug;7(8):913-9 [PMID: 11479623]
  8. Immunity. 1994 Jun;1(3):231-42 [PMID: 7889411]
  9. J Exp Med. 1995 Jul 1;182(1):75-85 [PMID: 7540658]
  10. Immunity. 1995 Dec;3(6):727-38 [PMID: 8777718]
  11. J Biol Chem. 1996 Jun 14;271(24):14445-51 [PMID: 8662890]
  12. Curr Opin Immunol. 1996 Dec;8(6):878-85 [PMID: 8994870]
  13. J Exp Med. 1997 Feb 3;185(3):531-9 [PMID: 9053453]
  14. J Exp Med. 1996 Sep 1;184(3):1093-9 [PMID: 9064326]
  15. Am J Pathol. 1997 Jun;150(6):1909-17 [PMID: 9176384]
  16. J Exp Med. 1987 Oct 1;166(4):1084-97 [PMID: 2443596]
  17. Cell. 1988 Mar 11;52(5):773-82 [PMID: 2449974]
  18. J Exp Med. 1989 Sep 1;170(3):827-45 [PMID: 2504877]
  19. Nature. 1990 Aug 30;346(6287):844-7 [PMID: 2118234]
  20. J Exp Med. 1991 Apr 1;173(4):869-79 [PMID: 1672545]
  21. Cell. 1991 Apr 19;65(2):305-17 [PMID: 1901764]
  22. Cell. 1991 Apr 19;65(2):319-31 [PMID: 1901765]
  23. Cell. 1992 Mar 6;68(5):869-77 [PMID: 1547488]
  24. Eur J Immunol. 1992 May;22(5):1115-21 [PMID: 1577058]
  25. Proc Natl Acad Sci U S A. 1992 Nov 1;89(21):10036-40 [PMID: 1279667]
  26. J Exp Med. 1993 Apr 1;177(4):1199-204 [PMID: 8096238]
  27. J Immunol. 1993 May 1;150(9):4136-50 [PMID: 7682590]
  28. Science. 1993 Apr 23;260(5107):547-9 [PMID: 8097338]
  29. Science. 1994 Jan 14;263(5144):235-7 [PMID: 7904381]
  30. J Clin Invest. 1994 Mar;93(3):1332-8 [PMID: 8132775]
  31. J Exp Med. 1994 May 1;179(5):1563-72 [PMID: 7909327]
  32. J Exp Med. 1994 Nov 1;180(5):1901-10 [PMID: 7525843]
  33. Endocr Rev. 1994 Aug;15(4):516-42 [PMID: 7988484]
  34. J Exp Med. 1995 Jan 1;181(1):381-6 [PMID: 7528773]
  35. J Exp Med. 1995 Feb 1;181(2):817-21 [PMID: 7836934]
  36. J Clin Invest. 1995 Feb;95(2):477-85 [PMID: 7860729]
  37. J Clin Invest. 1995 Feb;95(2):486-92 [PMID: 7860730]
  38. Immunity. 1994 May;1(2):155-66 [PMID: 7534199]
  39. J Immunol. 1999 Nov 15;163(10):5374-82 [PMID: 10553062]
  40. Curr Opin Immunol. 1999 Dec;11(6):670-6 [PMID: 10631553]
  41. Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):1976-81 [PMID: 10681428]
  42. J Virol. 2000 Apr;74(7):3284-92 [PMID: 10708445]
  43. Biochem Soc Trans. 1997 May;25(2):630-5 [PMID: 9191170]
  44. J Exp Med. 1998 Jan 5;187(1):129-34 [PMID: 9419219]
  45. J Exp Med. 1998 Feb 16;187(4):537-46 [PMID: 9463404]
  46. J Clin Invest. 1998 Feb 15;101(4):746-54 [PMID: 9466968]
  47. J Exp Med. 1998 Mar 16;187(6):875-83 [PMID: 9500790]
  48. Clin Immunol Immunopathol. 1998 Jul;88(1):4-13 [PMID: 9683544]
  49. Adv Immunol. 1998;70:83-243 [PMID: 9755338]
  50. J Immunol. 2000 Sep 1;165(5):2841-9 [PMID: 10946317]

Grants

  1. AI-41439/NIAID NIH HHS

MeSH Term

Adoptive Transfer
Animals
Chemokines
Diabetes Mellitus, Type 1
Immune Tolerance
Interleukin-12
Islets of Langerhans
Lymphocytic choriomeningitis virus
Mice
Mice, Transgenic
Th1 Cells

Chemicals

Chemokines
Interleukin-12

Word Cloud

Created with Highcharts 10.0.0IL-12cellsmicetgRIP-IL12betaantigen-specificTpancreaticbioactivepancreasdiseaseLCMVspontaneouslyactivateanti-self/viraldiabetesexpressionautoimmuneanalyzefunctionTh1-promotingcytokinevivogeneratedtransgenicwhoseconstitutivelyexpressonecomponentsp35p40contrastnon-tglittermatessingle-tgRIP-p35RIP-p40developedmarkedinfiltrationlymphocytesmacrophagesmainlyaroundisletsExpressionprimarilyupregulatedtranscriptlevelsIFN-inducibleprotein-10IP-10RANTESIFN-gammaTNF-alphaDespitesubstantialrecruitmentmononuclearbiochemicalclinicalevidentexocrineendocrineCoexpressionlymphocyticchoriomeningitisvirusproteinsfailedexpanduninfectedanimalsHoweverxRIP-LCMVinfectedinducedledaccelerationkineticsseverityinsulin-dependentmellitusIDDMThusectopicbreaktoleranceperipheryworsenongoingConstitutivecellperturbself-toleranceintensifiesestablished

Similar Articles

Cited By